Pharmaceutical

EC approves AstraZeneca’s acalabrutinib combo for CLL

The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.

Jun 9, 2025 - 06:00
EC approves AstraZeneca’s acalabrutinib combo for CLL
The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.
Read the original article

Tags:

Previous Article

The European Market Access Lag: 2021–2024

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Sanofi reports Q4 2024 increase in net income to $916m

Sanofi reports Q4 2024 increase in net income to $916m

Feb 1, 2025

Novartis snaps up rare disease biotech DTx Pharma in $1bn deal

Novartis snaps up rare disease biotech DTx Pharma in $1...

Jul 19, 2023

USPTO allows patents for Remedy’s large hemispheric infarction drug

USPTO allows patents for Remedy’s large hemispheric inf...

Mar 21, 2025